[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349442-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349442-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","olga-and-olgim-stages-for-predicting-metachronous-gastric-neoplasm-after-endoscopic-submucosal-dissection-research-study","OLGA and OLGIM Stages for Predicting Metachronous Gastric Neoplasm After Endoscopic Submucosal Dissection - Research Study","","This retrospective cohort study evaluates whether OLGA (operative link on gastritis assessment) and OLGIM (operative link on gastritis assessment based on intestinal metaplasia) can predict metachronous gastric neoplasms after endoscopic submucosal dissection (ESD) in early gastric cancer patients without current Helicobacter pylori infection. Among 494 EGC patients treated between 2004 and 2015, high risk (OLGA/OLGIM stage III–IV) showed higher metachronous incidence during 6.8-year median follow-up. The proposed staging supports optimizing post-ESD endoscopic surveillance intervals by risk.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/olga-and-olgim-stages-for-predicting-metachronous-gastric-neoplasm-after-endoscopic-submucosal-dissection-research-study/349442/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/olga-and-olgim-stages-for-predicting-metachronous-gastric-neoplasm-after-endoscopic-submucosal-dissection-research-study/349442.png","ImageObject",300,407,{"name":42,"@type":43},"Blitz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are OLGA and OLGIM used for in gastric cancer risk assessment?","Question",{"text":63,"@type":64},"OLGA and OLGIM are staging systems that evaluate the severity and extent of gastric atrophy and intestinal metaplasia, proposed to stratify gastric cancer risk.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who were included in this study and what treatment did they receive?",{"text":68,"@type":64},"The study enrolled 494 patients with early gastric cancer without current H. pylori infection who underwent endoscopic submucosal dissection (ESD) between 2004 and 2015.",{"name":70,"@type":61,"acceptedAnswer":71},"How did OLGA and OLGIM high-risk stages relate to metachronous neoplasm incidence?",{"text":72,"@type":64},"High-risk groups defined as OLGA or OLGIM stage III–IV had significantly higher metachronous neoplasm incidence than low-risk groups during follow-up.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349442,1790153417,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","J Gastric Cancer. 2026 Jul;26(3):420-432 [https://doi.org/10.5230/jgc.2026.26.e29](https://doi.org/10.5230/jgc.2026.26.e29)[ ](https://doi.org/10.5230/jgc.2026.26.e29)pISSN 2093-582X·eISSN 2093-5641  \nOriginal Article  \nReceived: Jan 31, 2026  \nRevised: Mar 25, 2026  \nAccepted: Apr 7, 2026  \nPublished online: May 18, 2026  \nCorrespondence to  \nIl Ju Choi  \nCenter for Gastric Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea.  \nEmail: [cij1224@ncc.re.kr](cij1224@ncc.re.kr)  \nCopyright © 2026. Korean Gastric Cancer Association.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://creativecommons.org/licenses/](https://creativecommons.org/licenses/)[ ](https://creativecommons.org/licenses/)[by-nc/4.0](by-nc/4.0)) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nYoung-Il Kim   \n[https://orcid.org/0000-0002-2614-3419](https://orcid.org/0000-0002-2614-3419)  \nMyeong-Cherl Kook   \n[https://orcid.org/0000-0002-3435-3301](https://orcid.org/0000-0002-3435-3301)  \nJong Yeul Lee   \n[https://orcid.org/0000-0001-8709-5097](https://orcid.org/0000-0001-8709-5097)  \nChan Gyoo Kim   \n[https://orcid.org/0000-0002-1651-2559](https://orcid.org/0000-0002-1651-2559)  \nIl Ju Choi   \n[https://orcid.org/0000-0002-8339-9824](https://orcid.org/0000-0002-8339-9824)  \nFunding  \nThis work was supported by grants (grant number: 2510760) from the National Cancer Center, Korea.  \nOLGA and OLGIM Stages for Predicting Metachronous Gastric Neoplasm After Endoscopic Submucosal Dissection in Patients With Early Gastric Cancer Without a Current Helicobacter pylori Infection Status  \nYoung-Il Kim , Myeong-Cherl Kook , Jong Yeul Lee , Chan Gyoo Kim , Il Ju Choi   \nCenter for Gastric Cancer, National Cancer Center, Goyang, Korea  \nABSTRACT  \nPurpose: The operative link on gastritis assessment (OLGA) and operative link on gastritis assessment based on intestinal metaplasia (OLGIM) are established tools for stratifying the risk of gastric neoplasm development. This study evaluated whether OLGA and OLGIM staging can predict metachronous gastric neoplasms (adenoma or cancer) after endoscopic submucosal dissection (ESD) in patients with early gastric cancer (EGC) without current Helicobacter pylori infection.  \nMaterials and Methods: This retrospective cohort study enrolled 494 patients with EGC without current H. pylori infection who underwent ESD between 2004 and 2015. The primary endpoint was the incidence of metachronous gastric neoplasms. High risk was defined as OLGA or OLGIM stage III–IV.  \nResults: Of the included patients, 55.4%(250/451) and 55.9%(276/494) were classified as high risk according to OLGA and OLGIM staging, respectively. During a median follow-up of 6.8 years, the incidence of metachronous gastric neoplasm was 26.6 cases per 1,000 personyears. According to OLGA staging, the high-risk group had a significantly higher incidence of metachronous neoplasms than the low-risk group (33.3 vs. 17.8 cases per 1,000 person-years, log-rank test P=0.012). Similarly, according to OLGIM staging, the high-risk group demonstrated a significantly higher incidence than the low-risk group (35.2 vs. 16.6 cases per 1,000 personyears, P=0.002) .  \nConclusions: In patients with EGC without current H. pylori infection, OLGA and OLGIM staging are useful for assessing the risk of metachronous gastric. The current 5-year endoscopic surveillance interval after ESD may be further optimized according to patient risk stratified by OLGA or OLGIM stages.  \nKeywords: Atrophy; Endoscopy; Gastric neoplasm; Helicobacter pylori  \n[https://jgc-online.org](https://jgc-online.org) 420  \nMetachronous Neoplasm and OLGA/OLGIM Stages  \nConflict of Interest  \nNo potential conflict of interest relevant to this article was reported.  \nAuthor Contributions  \nConceptualization: C. I.J.; Data cur","cbCaifPrT9jxi5C0","https://ap.wps.com/l/cbCaifPrT9jxi5C0","pdf",1059512,13,"English","# Abstract\n## Purpose\n## Materials and Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What are OLGA and OLGIM used for in gastric cancer risk assessment?\",\"answer\":\"OLGA and OLGIM are staging systems that evaluate the severity and extent of gastric atrophy and intestinal metaplasia, proposed to stratify gastric cancer risk.\"},{\"question\":\"Who were included in this study and what treatment did they receive?\",\"answer\":\"The study enrolled 494 patients with early gastric cancer without current H. pylori infection who underwent endoscopic submucosal dissection (ESD) between 2004 and 2015.\"},{\"question\":\"How did OLGA and OLGIM high-risk stages relate to metachronous neoplasm incidence?\",\"answer\":\"High-risk groups defined as OLGA or OLGIM stage III–IV had significantly higher metachronous neoplasm incidence than low-risk groups during follow-up.\"}]","OLGA and OLGIM Stages for Predicting Metachronous Gastric Neoplasm After Endoscopic Submucosal Dissection - Research Study | PDF",1790083324,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b046f12ce3ef349aeafeab70a72800ae.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e330935c4715665a57339e63eba7f79.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7614221a5b569317d5caf2673c5f251c.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f38a705fc165a1128acc2e7b0d5f5f30.webp",980,1306]